Pharmacology of heparins and direct anticoagulants;Pharmakologie der heparine und der direkten antikoagulanzien

Hamostaseologie

Volumn 28, Issue 5, 2008, Pages 400-420

  Alban, Susanne ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Argatroban; Bivalirduin; Dabigatran etexilate; Direct factor Xa inhibitors; Direct thrombin inhibitors; Fondaparinux; Glycosaminoglycans; Idraparinux; Lepirudin; Low molecular weight heparins; Rivaroxaban; SR123781A; Ximelagatran

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ANTICOAGULANT AGENT; ANTISTASIN; ANTITHROMBIN; ANTIVITAMIN K; APIXABAN; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; CERTOPARIN; DABIGATRAN; DABIGATRAN ETEXILATE; DALTEPARIN; DANAPAROID; DESULFATOHIRUDIN; ENOXAPARIN; FLAXIPARIN; FONDAPARINUX; GLYCOSAMINOGLYCAN POLYSULFATE; HEPARIN; HIRULOG; IDRAPARINUX; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MONOEMBOLEX; NADROPARIN; OLIGOSACCHARIDE; OTAMIXABAN; PHENPROCOUMON; PROTEIN; REVIPARIN; RIVAROXABAN; SR 123781A; SSR 126517E; TINZAPARIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; DRUG STRUCTURE; REVIEW;

EID: 58149471441     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1617187     Document Type: Review

References (160)

1. Abildgaard U. Heparin/low molecular weight heparin and tissue factor pathway inhibitor. Haemostasis 1993; 23 Suppl 1: 103-106.
2. Alban S, Gastpar R. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins. Thromb Haemost 2001; 85: 824-829.
3. th edition. New York: Marcel Dekker 2007; 67-116.
4. Alban S, Scriba GKE. Kommentar zur Monographie "Danaparoid sodium" PhEur 5.5, 2090. In: Arzneibuch-Kommentar. Band 5, Monographien D bis H. Stuttgart, Eschborn, Wissenschaftliche Verlagsgesellschaft, Govi-Verlag 2007; 26. Lieferung (PhEur 5.5).
5. Alban S. From heparins to factor Xa inhibitors and beyond. Eur J Clin Invest 2005; 35 Suppl I: 12-20.
6. Alban S. Kapitel 20. Kohlenhydrate III: Aminoglykane und Glykosaminoglykane. In: Hänsel R, Sticher O. (eds). Pharmakognosie - Phytopharmazie. Heidelberg: Springer 2006; 655-704.
7. Alban S. Paradigm change in anticoagulation. Natural substances that are selective factor Xa inhibitors. Pharm Unserer Zeit 2004; 33: 190-194.
8. Alban S. The 'precautionary principle' as a guide for future drug development. Eur J Clin Invest 2005; 35 Suppl I: 33-44.
9. Al Dieri R, Alban S, Beguin S et al. Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight. Thromb Haemost 2006; 4: 83-89.
10. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF et al. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group. Thromb Haemost 1994; 71: 698-702.
11. Amiral J, Lormeau JC, Marfaing-Koka A et al. Absence of cross-reactivity of SR90107A/ORG 31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997; 8: 114-117.
12. Ansell J, Hirsh J, Poller L et al. The pharmacology and management of the vitamin K antagonists. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 2004; 126: 204S-33S.
13. Barrowcliffe TW, Merton RE, Havercroft SJ et al. Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides. Thromb Res 1984; 34: 125-133.
14. Bartholomew JR, Hursting MJ. Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR). J Thromb Thrombolysis 2005; 19: 183-188.
15. Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invasive Cardiol 2000; 12 (Suppl F): 27F-32F.
16. Bates SM, Weitz JI. The status of new anticoagulants. Br J Haematol 2006; 134: 3-19.
17. Bauer KA, Hawkins DW, Peters PC et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors. Cardiovasc Drug Rev 2002; 20: 37-52.
18. Bauer KA. New anticoagulants. Hematology Am Soc Hematol Educ Program 2006: 450-456.
19. Bauer KA. New anticoagulants: anti IIa vs anti Xa - is one better? J Thromb Thrombolysis 2006; 21 (1): 67-72.
20. Bauersachs R, Alban S. Perioperative bridging with fondaparinux in a woman with antithrombin deficiency. Thromb Haemost 2007; 97: 498-499.
21. Beguin S, Welzel D, Al Dieri R et al. Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor Xa activity as a pharmaceutical mechanism and a yardstick for therapy. Haemostasis 1999; 29: 170-178.
22. Berry CN, Girardot C, Lecoffre C et al. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994; 72: 381-386.
23. Bianchini P, Liverani L, Spelta F et al. Variability of heparins and heterogeneity of low molecular weight heparins. Semin Thromb Hemost 2007; 33: 496-502.
24. Biemond BJ, Perzborn E, Friederich PW et al. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939) - an oral, direct factor Xa inhibitor. Thromb Haemost 2007; 97: 471-477.
25. Bijsterveld NR, Moons AH, Boekholdt SM et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-2554.
26. Björk I, Olson ST, Shore JD. Molecular mechanisms of the accelerating effect of heparin on the reactions between antithrombin and clotting proteinases. In: Lane DA, Lindahl U (eds). Heparin, chemical and biological properties, clinical applications. Boca Raton, Fl: CRC Press 1989; 229-256.
27. Blech S, Ebner T, Ludwig-Schwellinger E et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 386-399.
28. th edition. New York: Marcel Dekker 2007; 441-486.
29. Brufatto N, Ward A, Nesheim ME. Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex. J Thromb Haemost 2003; 1: 1258-1264.
30. Buller HR, van Doormaal FF, van Sluis GL et al. Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost 2007; Suppl 1: 246-254.
31. Cheng-Lai A. Cardiovascular drug highlight: hirudin. Heart Dis 1999; 1: 41-49.
32. Choay J, Petitou M, Lormeau JC et al. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-499.
33. Cines DB, Rauova L, Arepally G et al. Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. J Clin Apheresis 2007; 22: 31-36.
34. Collignon F, Frydman A, Caplain H et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995; 73: 630-640.
35. Crowther MA, Berry LR, Monagle PT et al. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 2000; 116: 178-186.
36. Dahlbäck B. Blood coagulation. Lancet. 2000; 355: 1627-1632.
37. Dawa J, Pepper DS. Catabolism of low-dose in man. Thromb Res 1986; 43: 1-6.
38. Depasse F, Gonzalez de Suso MJ, Lagoutte I et al. Comparative study of the pharmacokinetic profiles of two LMWHs - bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa) - administered subcutaneously to healthy male volunteers. Thromb Res 2003; 109: 109-117.
39. Di Nisio M, Middeldorp S, Büller HR. Direct thrombin inhibitors. N Engl J Med 2005; 353: 1028-1040.
40. Dunwiddie C, Thornberry NA, Bull HG et al. Antistasin, a leech-derived inhibitor of factor Xa. Kinetic analysis of enzyme inhibition and identification of the reactive site. J Biol Chem 1989; 264: 16694-16699.
41. Dyke CM, Aldea G, Koster A et al. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies. Ann Thorac Surg 2007; 84: 836-839.
42. Eisenberg PR, Siegel JE, Abendschein DR et al. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993; 91: 1877-1883.
43. EMEA. European Public Assessment Report for Angiox. H-C-562-N-12.13.07. 2007. http://www.emea.europa.eu/humandocs/Humans/EPAR/angiox/angiox.htm. Accessed: 13.05.2008.
44. EMEA. European Public Assessment Report for Refludan. H-C-122-IA-31. 15.10.2007. http://www.emea.europa.eu/humandocs/Humans/EPAR/refludan/refludan. htm. Accessed: 13.05.2008.
45. FDA, CDER. Label information for Angiomax, NDA 20-873/S-011. 30.11.2005. http://www.fda.gov/cder/foi/label/2005/020873s011lbl.pdf. Accessed: 13.05.2008.
46. FDA, CDER. Label information for Argatroban, 20-883/S-004. 04.03.2002. http://www.fda.gov/cder/foi/label/2002/20883s4lbl.pdf. Accessed: 13.05.2008.
47. FDA, CDER. Label information for Refludan, 20-807/S-015. 11.07.2006. http://www.fda.gov/cder/foi/label/2006/020807s011lbl.pdf. Accessed: 13.05.2008.
48. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 1996; 26 Suppl 2: 24-38.
49. Garon JE. Monitoring low molecular weight heparins. Clin Leadersh Manag Rev 2003; 17: 47-50.
50. Gerotziafas GT, Elalamy I, Depasse F et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007; 5: 886-888.
51. Goldkind L, Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf 2006; 15: 213-220.
52. Graff J, von Hentig N, Misselwitz F et al. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007; 47: 1398-1407.
53. Gray E, Cesmeli S, Lormeau JC et al. Low affinity heparin is an antithrombotic agent. Thromb Haemost 1994; 71: 203-207.
54. Greinacher A, Alban S, Dummel V et al. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocvtopenia. Thromb Haemost 1995; 74: 886-892.
55. Greinacher A, Alban S, Orner-Adam MA et al. Heparin-induced thrombocytopenia: A stoichiometry-based model to explain the different immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux. Thromb Res 2008; 122: 211-220.
56. Greinacher A, Gopinadhan M, Gunther JU et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 2006; 26: 2386-2389.
57. Guzzi LM, McCollum DA, Hursting MJ. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia. J Thromb Thrombolysis 2006; 22: 169-176.
58. Hamano S, Nishiyama M, Kikuchi S et al. Study of low molecular weight heparin effect on the relation between anticoagulant activity and antithrombin III affinity. Thromb Res 1992; 66: 299-307.
59. Hara T, Yokoyama A, Ishihara H et al. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor for factor Xa. Thromb Haemost 1994; 71: 314-319.
60. Harder S, Graff J, Klinkhardt U et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time. Thromb Haemost 2004; 91: 1137-1145.
61. Hauel NH, Nar H, Priepke H et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002; 45: 1757-1766.
62. Hauptmann J, Kaiser B, Nowak G et al. Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors. Thromb Haemost 1990; 63: 220-223.
63. Hérault JP, Bernat A, Pflieger AM et al. Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. J Pharmacol Exp Ther 1997; 283: 16-22.
64. Herault JP, Bernat A, Roye F et al. Pharmacokinetics of new synthetic heparin mimetics. Thromb Haemost 2002; 87: 985-989.
65. Herbert JM, Herault JP, Bernat A et al. SR123781A, a synthetic heparin mimetic. Thromb Haemost 2001; 85: 852-860.
66. Hirsh J, Raschke R. Heparin and low moleuclar weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 188S-203S.
67. Hjelm R, Schedin-Weiss S. High affinity interaction between a synthetic, highly negatively charged pentasaccharide and alpha- or beta-antithrombin is predominantly due to nonionic interactions. Biochemistry 2007; 46: 3378-3384.
68. rd. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-965.
69. http://climcaltrials.gov/ct2/results?intr=%22SR123781A%22. Accessed: 13.05.2008.
70. Hursting MJ, Lewis BE, Macfarlane DE. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 2005; 11: 79-87.
71. Ieko M. Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke. Curr Opin Investig Drugs 2007; 8: 758-768.
72. Irie A, Takami M, Kubo H et al. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone 2007; 41: 165-174.
73. Jeske W, Lormeau JC, Callas D et al. Antithrombin III affinity dependence on the anticoagulant, antiprotease, and tissue factor pathway inhibitor actions of heparins.Semin Thromb Hemost 1995; 21: 193-200.
74. Jurk K, Kehrel BE. Platelets and the new comprehension of haemostasis. Hamostaseologie 2005; 25: 39-49.
75. Kakar P, Watson T, Lip GY. Rivaroxaban. Drugs Today (Barc) 2007; 43: 129-136.
76. Kakkar AK, Brenner B, Dahl OE et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.
77. Kenne K, Skanberg I, Glinghammar B et al. Prediction of drug-induced liver injury in humans by using in vitro methods: the case of ximelagatran. Toxicol In Vitro 2008; 22: 730-746.
78. Kikumoto R, Tamao Y, Tezuka T et al. Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl) sulfonyl]-1-arginyl)]-2-piperidinecarboxylic acid. Biochemistry 1984; 23: 85-90.
79. Klement P, Rak J. Emerging anticoagulants: mechanism of action and future potential. Vnitr Lek 2006; 52 Suppl 1: 119-122.
80. Koopman MM, Buller HR. Short- and long-acting synthetic pentasaccharides. J Intern Med 2003; 254: 335-342.
81. Koster A, Dyke CM, Aldea G et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 2007; 83: 572-577.
82. Kubitza D, Becka M, Mueck W et al. Rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 2007; 63: 469-476.
83. Kubitza D, Becka M, Mueck W et al. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct factor Xa inhibitor - are not affected by aspirin. J Clin Pharmacol 2006; 46: 981-990.
84. Kubitza D, Becka M, Voith B et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-421.
85. Kubitza D, Becka M, Zuehlsdorf M et al. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007; 47: 218-226.
86. Kubitza D, Becka M, Zuehlsdorf M et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006; 46: 549-558.
87. Laforest MD, Linhart CN, Guiraud-Vitaux F et al. Pharmakokinetics and biotransformation of technetium 99m labelled standard heparin and a low molecular weight heparin (enoxaparin) after intravenous injection innormal volunteers. Br J Haematol 1991; 77: 201-208.
88. Lassen MR, Ageno W, Borris LC et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
89. Laux V, Perzbora E, Kubitza D et al. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Semin Thromb Hemost 2007; 33: 515-523.
90. th edition. New York: Marcel Dekker 2007; 67-116.
91. Leizorovicz A, Bara L, Samama MM et al. Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis 1993; 23 Suppl 1: 89-98.
92. Levine MN, Raskob G, Beyth RJ et al. Hemorrhagic complications of anticoagulant treatment: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 287S-310S.
93. Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 2006; 129: 1167-1175.
94. Liesenfeld KH, Schäfer HG, Trocóniz IF et al. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006; 62: 527-537.
95. Lim W, Dentali F, Eikelboom JW et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 673-684.
96. Lindahl U, Kusche-Gullberg M, Kjellén L. Regulated diversity of heparan hulfate. J Biol Chem 1998; 273: 24979-24982.
97. Lormeau JC, Herault JP. The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thromb Haemost 1995; 74: 1474-1477.
98. Ludwig RJ, Alban S, Bistrian R et al. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thromb Haemost 2006; 95: 535-540.
99. Ludwig RJ, Alban S, Boehncke WH. Structural requirements of heparin and related molecules to exert a multitude of anti-inflammatory activities. Mini Rev Med Chem 2006; 6: 1009-1023.
100. Mahé I, Aghassarian M, Drouet L et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 2007; 97: 581-586.
101. Massonnet-Castel S, Pelissier E, Bara L et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis 1986; 16: 139-146.
102. Matthai WH Jr. Safety and efficacy of argatroban in patients with heparin-induced thrombocytopenia. Curr Hematol Rep 2006; 5: 95-99.
103. Merton RE, Thomas DP, Havercroft SJ et al. High and low affinity heparin compared with unfractionated heparin as antithrombotic drugs. Thromb Haemost 1984; 51: 254-256.
104. Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 2006; 26: 41-48.
105. Mueck W, Becka M, Kubitza D et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor xa inhibitor - in healthy subjects. Int J Clin Pharmacol Ther 2007; 45: 335-344.
106. Mueck W, Eriksson BI, Bauer KA et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008; 47: 203-216.
107. Mungall D. BIBR-1048 Boehringer Ingelheim. Curr Opin Investig Drugs 2002; 3: 905-907.
108. N.N. Danaparoid sodium. European Pharmacopoeia 5.5 2006; No. 07/2006:2090.
109. N.N. Low molecular weight heparins. European Pharmacopoeia 5.0 2004; No. 2318
110. Nagahara T, Yokoyama Y, Inamura K et al. Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors. J Med Chem 1994; 37: 1200-1207.
111. Nelson-Piercy C. Hazards of heparin: allergy, heparin-induced thrombocytopenia and osteoporosis. Baillieres Clin Obstet Gynaecol 199; 11: 489-509.
112. Nieuwenhuis HK, Albada J, Banga JD et al. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991; 78: 2337-2343.
113. Norrby K. Low-molecular-weight heparins and angiogenesis. APMIS 2006; 114: 79-102.
114. Ofosu FA. Antithrombotic mechanisms of heparin and related compounds. In: Lane DA, Lindahl U (eds). Heparin, chemical and biological properties, clinical applications. Boca Raton, Fl: CRC Press 1989; 433-454.
115. Okamoto S, Hijikata A, Kikumoto R et al. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereostructure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981; 101: 440-446.
116. Olson ST, Björk I, Sheffer R et al. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem 1992; 267: 12528-12538.
117. Papadopoulos S, Flynn JD, Lewis DA. Fondaparinux as a treatment option for heparin-induced thrombocytopenia. Pharmacotherapy 2007; 27: 921-926.
118. Perzborn E, Kubitza D, Misselwitz F. Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. Hamostaseologie 2007; 27: 282-289.
119. Perzbom E, Strassburger J, Wilmen A et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-521.
120. Petitou M, Driguez PA, Duchaussoy P et al. Synthetic oligosaccharides having various functional domains: potent and potentially safe heparin mimetics. Bioorg Med Chem Lett 1999; 9: 1161-1166.
121. Petitou M, Duchaussoy P, Driguez PA et al. New synthetic heparin mimetics able to inhibit thrombin and factor Xa. Bioorg Med Chem Lett 1999; 9: 1155-1160.
122. Petitou M, Duchaussoy P, Jaurand G et al. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540). J Med Chem 1997; 40: 1600-1607.
123. Petitou M, Herault JP, Bernat A et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 1999; 398: 417-422.
124. Pouplard C, Couvret C, Regina S et al. Development of antibodies specific to polyanion-modified platelet factor 4 during treatment with fondaparinux. J Thromb Haemost 2005; 3: 2813-2815.
125. Rauova L, Poncz M, McKenzie SE et al. Ultra-large complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2005; 105: 131-138.
126. Rezaie AR. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood 2001; 97: 2308-2313.
127. Roehrig S, Straub A, Pohlmann J et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-{3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005; 48: 5900-5908.
128. rd ed. Philadelphia, PA: JB Lippincott 1994; 837-860.
129. Sanofi-Aventis. Idraparinux shows encouraging results in van Gogh clinical trials program. Press release 10.12.2006.
130. Schwienhorst A. Direct thrombin inhibitors - a survey of recent developments. Cell Mol Life Sci 2006; 63: 2773-2791.
131. Serebruany MV, Malinin AI, Serebruany VL. Argatroban, a direct thrombin inhibitor for heparin-induced thrombocytopaenia: present and future perspectives. Expert Opin Pharmacother 2006; 7: 81-89.
132. Simonis D, Fritzsche J, Alban S et al. Kinetic analysis of heparin and glucan sulfates binding to P-selectin and its impact on the general understanding of selectin inhibition. Biochemistry 2007; 46: 6156-6164.
133. Sitko GR, Ramjit DR, Stabilito I et al. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 1992; 85: 805-815.
134. Smogorzewska A, Brandt JT, Chandler WL et al. Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing. Arch Pathol Lab Med 2006; 130: 1605-1611.
135. Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001; 53: 93-105.
136. Stangier J, Eriksson BI, Dahl OE et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 555-563.
137. Stangier J, Rathgen K, Stähle H et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303.
138. Steinmetzer T, Stürzebecher J. From fibrinogen and hirudin to synthetic anticoagulants. Rational design of thrombin inhibitors. Pharm Unserer Zeit 2004; 33: 196-205.
139. Steinmetzer T, Stürzebecher J. Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants. Curr Med Chem 2004; 11: 2297-2321.
140. Stephens JL, Koerber JM, Mattson JC et al. Effect of lepirudin on the international normalized ratio. Ann Pharmacother 2005; 39: 28-31.
141. Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins - correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res 2005; 11: 7003-7011.
142. Stringer KA, Lindenfeld J. Hirudins: antithrombin anticoagulants. Ann Pharmacother 1992; 26: 1535-1540.
143. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20: 318-329.
144. Swan SK, St Peter JV, Lambrecht LJ et al. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000; 20: 756-770.
145. Turpie A, Bauer K, Davidson B et al. Comparison of rivaroxaban - an oral, direct factor Xa inhibitor - and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD4: a phase 3 study). European Federation of National Associations of Orthopaedics and Traumatology (EFFORT) 2008 Annual Meeting; May 29-June 1, 2008; Nice, France. Abstract F85.
146. Tuszynski GP, Gasic TB, Gasic GJ. Isolation and characterization of antistasin. An inhibitor of metastasis and coagulation. J Biol Chem 1987; 262: 9718-9723.
147. Valentin S, Ostergaard P, Kristensen H et al. Synergism between full length TFPI and heparin: evidence for TFPI as an important factor for the antithrombotic activity of heparin [letter]. Blood Coagul Fibrinolysis 1992; 3: 221-222.
148. van Gogh Investigators. Buller HR, Cohen AT et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357: 1094-1104.
149. van Gogh Investigators, Buller HR, Cohen AT et al. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007; 357: 1105-1112.
150. Vlasuk GP, Ramjit D, Fujita T et al. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemost 1991; 65: 257-262.
151. Warkentin TE, Cook RJ, Marder VJ et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005; 106: 3791-3796.
152. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356: 2653-2655.
153. Waxman L, Smith DE, Arcuri KE et al. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990; 248: 593-596.
154. Weitz J, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected frominhibition by heparinantithrombin but susceptible to inactivation by antithrombinindependent inhibitors. Circulation 1998; 97: 544-552.
155. Weitz JI, Crowther M. Direct thrombin inhibitors. Thromb Res 2002; 106: V275-284.
156. Weitz JI. A novel approach to thrombin inhibition. Thromb Res 2003; 109 Suppl 1: S17-22.
157. Wienen W, Stassen JM, Priepke H et al. Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis. J Thromb Haemost 2007; 5: 1237-1242.
158. Wienen W, Stassen JM, Priepke H et al. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Thromb Haemost 2007; 98: 333-338.
159. Wienen W, Stassen JM, Priepke H et al. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007; 98: 155-162.
160. Yu G, LeBrun L, Gunay NS et al. Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding site. Thromb Res 2000; 100: 549-556.